Traditional Chinese oral solution and mouthwash to shorten severe radiation-induced mouth sores in head and neck cancer.
Official title: Chinese Herbal Oral Solution and Mouthwash Shorten the Duration of Severe Radiotherapy-induced Oral Mucositis in Patients With Head and Neck Malignancies.
Run by West China Hospital · NCT07339774 · Data updated 2026-11-12
This trial will try a combined traditional Chinese oral solution and mouthwash to shorten and ease severe radiation-induced mouth sores in adults receiving radiotherapy for head and neck cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 128 (estimated) |
| Sponsor | West China Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | November 5, 2026 |
| Main results expected | May 31, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07339774 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with non-metastatic head and neck cancer undergoing radiotherapy (or concurrent chemoradiotherapy) who develop RTOG grade ≥3 oral mucositis, have ECOG ≤2, and adequate organ function.
✕Probably not a fit
Patients with prior head and neck radiotherapy, active severe periodontal disease, recent use of antibiotics/antifungals or antimicrobial mouthwash, planned therapy with EGFR inhibitors or immune checkpoint inhibitors, multiple drug allergies, or other serious comorbidities may not benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized phase 2 trial enrolls adults with non-metastatic head and neck cancer who develop severe radiation-induced oral mucositis (RTOG grade ≥3) during radiotherapy. Participants start treatment the first day severe mucositis appears and receive Zishui Daohuo oral solution three times daily plus Kuju mouthwash six times daily, or matched placebos. Treatment continues until two weeks after radiotherapy, and patients are asked to avoid eating, drinking, or oral hygiene for one hour after each use to maximize mucosal contact. Primary outcomes include duration of severe mucositis and safety/adverse events compared between the TCM combination and placebo groups.
Why it matters
Potential benefit: If successful, the regimen could shorten time with severe mouth sores, reduce pain, and help patients complete radiotherapy with better oral comfort.
How similar studies have gone: Some small trials of topical or herbal preparations have suggested benefit for radiation mucositis, but high-quality evidence for this specific TCM combination is limited and further testing is needed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients pathologically diagnosed with non-metastatic head and neck malignant tumors; 2. Age range: 18 to 65 years old (including 18 and 65 years old); 3. Eastern Cooperative Oncology Group performance status of ≤2; 4. Radiotherapy or concurrent chemoradiotherapy is required; 5. The main organ functions well; 6. Sign informed consent. Exclusion Criteria: 1. Allergic constitution (such as those known to be allergic to two or more drugs); 2. Patients who plan to use drugs that can cause or worsen oral mucosal inflammation (such as anti EGFR monoclonal antibodies, immune checkpoint inhibitors, etc.) after the start of radiotherapy; 3. Use of antibiotics, antifungal drugs, or antimicrobial mouthwash within 1 month of the study; 4. Poor oral hygiene and/or severe periodontal diseases; 5. History of head and neck radiotherapy; 6. Deemed unsuitable for the study by the investigators (concomitant with any other severe diseases).
Where it's running
-
West China Hospital
Chengdu, Sichuan, China Recruiting
Study contacts
- Principal investigator: Xingchen Peng, Professor — West China Hospital
- Study coordinator: Xingchen Peng Professor
- Email: pxx2014@163.com
- Phone: +8618980606753
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding metal elements in radiation-induced mouth sores
This study is trying to see if certain metal elements in the body can help predict how severe mouth sores will be for patients getting radiation treatment for head and neck cancer.
-
Using breath analysis to predict mouth sores from radiotherapy in head and neck cancer patients
This study is testing whether analyzing breath samples can help predict mouth sores in head and neck cancer patients receiving radiotherapy.
-
Assessing SAA1 Levels to Predict Oral Mucositis from Radiotherapy
This study is testing if measuring a specific protein in the blood can help predict how severe mouth sores will be for patients with head and neck cancer who are getting radiation treatment.
-
Houyanqing oral liquid to prevent and treat radiation mouth sores in nasopharyngeal cancer
This phase 3 trial will test whether adding Houyanqing oral liquid to standard care can prevent or lessen radiation-caused mouth sores in adults receiving radiotherapy for nasopharyngeal cancer.
-
TCM oral liquid plus herbal mouthwash for radiation‑caused mouth sores in head and neck cancer
This study will test whether taking a Qingying oral liquid and using a modified Da Huang‑Huang Lian Xiexin mouthwash can reduce how often, how long, and how severe radiation‑induced mouth sores are in adults receiving radiotherapy for head and neck cancer.
-
Rice bran for radiation-related mouth sores in head and neck cancer
This trial will try rice bran supplements during radiation to see if adults with head and neck cancer have fewer or less severe mouth sores.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.